Jazz Pharmaceuticals (JAZZ) PT Lowered to $172 at UBS; 'Lowering Erwinase & Defitelio Sales Estimates' on Symphony Sales Data
Tweet Send to a Friend
UBS lowered its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $172.00 (from $175.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
